Chyme Reinfusion for Type 2 Intestinal Failure (REINFUSE)
Pivotal Study to Evaluate the Safety and Efficacy of the Insides™ System in the Treatment of Subjects With a Double Enterostomy and/or Enterocutaneous Fistula and Type 2 Intestinal Failure.
Sponsor: BioValeo
Listed as NCT04577456, this NA trial focuses on Enterocutaneous Fistula and High Output Stoma and remains completed. Sponsored by BioValeo, it has been updated 14 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Jan 2026 — Present [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Oct 2025 — Jan 2026 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Oct 2025 [monthly]
Recruiting NA
-
Dec 2024 — Jun 2025 [monthly]
Recruiting NA
-
Nov 2024 — Dec 2024 [monthly]
Recruiting NA
▶ Show 9 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Sep 2023 — Jul 2024 [monthly]
Recruiting NA
-
Feb 2023 — Sep 2023 [monthly]
Recruiting NA
Status: Withheld → Recruiting · Phase: None → NA
-
Jul 2022 — Feb 2023 [monthly]
Withheld
-
May 2022 — Jul 2022 [monthly]
Withheld
-
Dec 2021 — May 2022 [monthly]
Withheld
-
Jan 2021 — Dec 2021 [monthly]
Withheld
-
Nov 2020 — Jan 2021 [monthly]
Withheld
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BioValeo
- Databean
- Green Lane Coordinating Centre Limited
- The Insides Company
For direct contact, visit the study record on ClinicalTrials.gov .